23 completed, 15 terminated, 11 unknown, 10 withdrawn. 61 Phase 2, 14 Phase 3, 8 Phase 1.
Follow COVID: new trials by email Literature Review of COVID trials Research Report on COVID
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients Pentoxifylline, Placebo - COVID | Phase 1 / Phase 2 | Withdrawn | Sadat City University | 2022-11-13 | 2023-01-18 | |
| Niclosamide In Moderate COVID-19 Niclosamide Oral Tablet, Placebo - COVID | Phase 2 | Withdrawn | Entero Therapeutics | 2022-01-20 | 2022-02-21 | |
| Maintenance Versus Reduction of Immunosuppression for Renal Transplant Patients Hospitalized With COVID-19 Disease Maintenance or reduction of immunosuppression - COVID, Kidney Transplant; Complications | Phase 2 / Phase 3 | Withdrawn | Brigham and Women's Hospital | 2021-05-03 | 2022-05-04 | |
| Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19 ZYESAMI™ (aviptadil acetate), Placebo, Nebulized administration of ZYESAMI™ or Placebo - SARS-CoV 2, COVID | Phase 2 / Phase 3 | Terminated | APR Applied Pharma Research s.a. | 144 | 2021-02-15 | 2023-02-03 |
| Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients Ivermectin Injectable Solution, Injectable Placebo, Zinc - Coronavirus Infection, COVID | Phase 1 / Phase 2 | Unknown | Sohaib Ashraf | 180 | 2020-11-14 | 2021-02-17 |
| Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19 PLX-PAD - COVID, ARDS | Phase 2 | Terminated | Pluristem Ltd. | 23 | 2020-10-19 | 2024-08-29 |
| LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) LSALT peptide, Placebo - COVID, Severe Acute Respiratory Syndrome | Phase 2 | Completed | Arch Biopartners Inc. | 61 | 2020-10-14 | 2025-07-09 |
| Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19 PLX-PAD, Placebo - COVID, ARDS | Phase 2 | Terminated | Pluristem Ltd. | 66 | 2020-10-01 | 2024-08-30 |
| P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 P2Et (Caesalpinia spinosa extract), Placebo - COVID, Coronavirus Infection | Phase 2 / Phase 3 | Unknown | Hospital Universitario San Ignacio | 100 | 2020-09-30 | 2021-08-10 |
| Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease N-acetylcysteine - COVID, Sars-CoV2 | Phase 2 | Completed | Cambridge Health Alliance | 165 | 2020-09-23 | 2021-05-28 |
| Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease NP-120 (Ifenprodil) - COVID | Phase 2 / Phase 3 | Completed | Algernon Pharmaceuticals | 168 | 2020-08-05 | 2021-12-03 |
| The Açaí Berry COVID-19 Anti-Inflammation Trial Açaí palm berry extract - natural product, Placebo - COVID | Phase 2 | Unknown | University Health Network, Toronto | 480 | 2020-08-04 | 2022-05-31 |
| Sofosbuvir in Treatment of COVID 19 sofosbuvir, Sofosbuvir ledipsavir, Daclatasvir - COVID | Phase 2 / Phase 3 | Unknown | Tanta University | 60 | 2020-08-01 | 2020-12-08 |
| An Adaptive Clinical Trial of Antivirals for COVID-19 Infection Favipiravir - COVID | Phase 2 | Unknown | Bayside Health | 190 | 2020-07-30 | 2021-10-07 |
| Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation mavrilimumab, Placebo - COVID | Phase 2 / Phase 3 | Completed | Kiniksa Pharmaceuticals International, plc | 814 | 2020-07-28 | 2025-01-22 |
| Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection Placebo, Ivermectin, Losartan - Cancer, COVID | Phase 2 | Terminated | Instituto do Cancer do Estado de São Paulo | 77 | 2020-07-23 | 2022-08-09 |
| Use of Convalescent Plasma for COVID-19 Convalescent Plasma - COVID | Phase 2 | Terminated | Northside Hospital, Inc. | 8 | 2020-07-14 | 2022-11-14 |
| Pulmozyme to Improve COVID-19 ARDS Outcomes Pulmozyme, Placebo - COVID | Phase 2 | Unknown | Boston Children's Hospital | 60 | 2020-07-05 | 2021-12-17 |
| Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS Ruxolitinib administration - ARDS, Human, COVID | Phase 2 | Completed | Philipps University Marburg | 15 | 2020-07-01 | 2021-08-24 |
| A Study of Combination Therapies to Treat COVID-19 Infection hydroxychloroquine, Azithromycin, Ritonavir - COVID, COVID-19 | Phase 2 | Withdrawn | ProgenaBiome | 2020-07-01 | 2021-04-08 |
Showing 20 of 61. Sign in to see all of them.
COVID-19 (23) · Coronavirus Infections (19) · Respiratory Distress Syndrome (9) · Pneumonia (5) · Severe Acute Respiratory Syndrome (4) · Acute Lung Injury (2) · Cytokine Release Syndrome (2) · Pneumonia, Viral (2) · Acute Kidney Injury (1) · Disseminated Intravascular Coagulation (1) · Dyspnea (1) · Hemostatic Disorders (1) · Inflammation (1) · Lung Diseases, Interstitial (1) · Neoplasms (1)
Infections (31) · Respiratory Tract Diseases (31) · Coronaviridae Infections (30) · Lung Diseases (30) · Nidovirales Infections (30) · RNA Virus Infections (30) · Virus Diseases (30) · Respiratory Tract Infections (27) · Pneumonia, Viral (22) · Pneumonia (20) · Coronavirus Infections (11) · Respiration Disorders (9) · Pathological Conditions, Signs and Symptoms (3) · Lung Injury (2) · Pathologic Processes (2)
Ivermectin (7) · Hydroxychloroquine (5) · Standard of Care (3) · Azithromycin (2) · Chloroquine (2) · Lopinavir (2) · Ritonavir (2) · Saline Solution (2) · Vitamin D (2) · Zinc (2) · favipiravir (2) · sarilumab (2) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1) · Acetylcysteine (1) · Artesunate (1)
Tanta University (5) · Pluristem Ltd. (2) · ProgenaBiome (2) · Zagazig University (2) · APR Applied Pharma Research s.a. (1) · Algernon Pharmaceuticals (1) · Apellis Pharmaceuticals, Inc. (1) · Arch Biopartners Inc. (1) · Assistance Publique Hopitaux De Marseille (1) · Azienda Ospedaliero, Universitaria Pisana (1) · BayCare Health System (1) · Bayside Health (1) · Boston Children's Hospital (1) · Brigham and Women's Hospital (1) · CTI BioPharma (1)
United States (25) · Egypt (8) · Brazil (4) · Italy (3) · Australia (2) · Canada (2) · Colombia (2) · Denmark (2) · Germany (2) · Spain (2) · Austria (1) · Belarus (1) · Chile (1) · France (1) · Hong Kong (1)
Sabine Hazan, MD (2) · Ahmad Ameri, Prof. (1) · Ana Andreazza, PhD (1) · Anca Askanase, MD, MPH (1) · Andreas Neubauer, Prof Dr. (1) · Andrei Y Hancharou, Dr. (1) · Andri MT Lubis, MD, PhD (1) · Asger Granfeldt, MD, PhD (1) · Bodil S Rasmussen, MD, PhD (1) · Danielle Mauck, BA (1) · Eduard A Dotsenko, Dr., prof. (1) · Elliott Bennett-Guerrero, MD (1) · Emilie Garrido-Pradalie (1) · Francesco Menichetti (1)
PMID 34013969, PMID 34473343, PMID 36734509, PMID 37162745, PMID 37489818, PMID 32150360, PMID 32219428, PMID 32228825, PMID 32303365, PMID 32788708, PMID 32883593, PMID 32951151, PMID 33044747, PMID 33050947, PMID 33240091, PMID 33492523, PMID 33870923, PMID 34385593, PMID 34488858, PMID 34755269, PMID 35213547, PMID 36160152, PMID 36218354, PMID 36469321, PMID 36695483, PMID 36782325, PMID 38490660